



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx) to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

## Arzerra® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>		Directions for Use:	
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>			

Clinical Information <small>(required)</small>	
<b>Select the diagnosis below:</b>	
<input type="checkbox"/> Chronic lymphocytic leukemia (CLL)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
<b>Clinical Information:</b>	
Is this a continuation of prior Arzerra therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient been on Arzerra within the past 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Is Arzerra prescribed by or in consultation with an oncologist/hematologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Select if the following applies to the patient:	
<input type="checkbox"/> Disease is recurrent or progressive	<input type="checkbox"/> Disease has relapsed
<input type="checkbox"/> Disease is refractory	<input type="checkbox"/> Previously untreated disease
<b>For recurrent or progressive CLL, also answer the following:</b>	
Will Arzerra be used for the extended treatment of patients who are in complete or partial response after at least two lines of therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
<b>For refractory CLL, also answer the following:</b>	
Select if the patient is refractory to the following CLL regimens:	
<input type="checkbox"/> Campath (alemtuzumab)	
<input type="checkbox"/> Fludara (fludarabine)	
<b>For relapsed CLL, also answer the following:</b>	
Will Arzerra be used in combination with fludarabine AND cyclophosphamide? <input type="checkbox"/> Yes <input type="checkbox"/> No	
<b>For previously untreated CLL, also answer the following:</b>	
Is the patient an appropriate candidate for fludarabine-based therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Will Arzerra be used in combination with chlorambucil? <input type="checkbox"/> Yes <input type="checkbox"/> No	

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

Please note: This request may be denied unless all required information is received.  
 If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.  
 For urgent or expedited requests please call 1-800-711-4555.  
 This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**  
 Office use only: Arzerra\_CMS\_2018Feb-W